Please login to the form below
aflibercept
This page shows the latest aflibercept news and features for those working in and with pharma, biotech and healthcare.
Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD
Beovu (brolucizumab) is the first anti-VEGF treatment to demonstrate superior resolution of retinal fluid compared to Eylea (aflibercept) in patients with wet age-related macular degeneration (AMD), according to Novartis. ... aflibercept) squaring off
Latest news
-
Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture
s Eylea (aflibercept), which together account for the lion’s share of the wet AMD market by value.
-
Novartis bags US okay for Lucentis follow-up Beovu in wet AMD
Novartis’ drug was the first VEGF inhibitor to reach the market for wet AMD but is facing the triple challenge of Bayer/Regeneron’s rival drug Eylea (aflibercept) – now the market
-
Alnylam swaps Sanofi for Regeneron as R&D partner
Regeneron will however take the lead on eye disease candidates, a category in which it is already strong with blockbuster age-related macular degeneration (AMD) therapy Eylea (aflibercept), with Alnylam in
-
After Lucentis setback, Novartis trumpets data on follow-up drug
The experimental therapy – called brolucizumab (RTH258) – showed its was superior to a Bayer and Regeneron’s Eylea (aflibercept) in tackling a key disease activity marker in age-related macular degeneration (AMD),
-
NHS wins legal fight with pharma over off-label Avastin
Bayer's Eylea (aflibercept) and Novartis' Lucentis (ranibizumab) are among the top selling drugs in England, number 2 and number 5 in the top ten medicines by spending in the
More from news
Approximately 17 fully matching, plus 60 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2016
330. Ocular Therapeutics (US). Regeneron (US). Licence collaboration. Hydrogel sustained release aflibercept (Eylea) for wet macular degeneration.
-
Deal Watch March 2016
Collaboration &licence. $134. Regeneron/ Bayer. Ophthalmology combination therapy: nesvacumab (Ang2 antibody) and aflibercept (VEGF trap).
-
Interview: Beate Wieseler, IQWIG
In addition fellow German firm Bayer criticised IQWiG's assessment of trial designs after the HTA body deemed data for eye drug Eylea (aflibercept) unsuitable in order to judge its
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Biogen and Happify Health team up to create digital platform for MS patients
- Moderna to launch Innovation and Technology Center in the UK
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Live Webinar: Navigating the Nuances of Europe's MedTech Industry
- Why project managers are key to creating quality content
- Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- A creative awakening – how pharma is bringing innovation to the patient journey
- AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
PMHub
OPEN Health
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
